Account
Hero background pattern

We’ll launch your pharmaceuticals to new heights

Specialist and experienced pricing and market access consultancy

News

ISPOR Europe 2024

We’re delighted to announce our participation at ISPOR Europe 2024 in Barcelona this November. We’ll…
Read more
Insider Insights

Worldwide: New Coalition to improve access to canc…

According to the UICC, “priority will be given to medicines currently on the WHO Essential Medicin…
Read more
Insider Insights

World’s first CRISPR medicine approved in UK for…

The MHRA grants conditional approval to Casgevy, the first-ever CRISPR gene-editing therapy for sick…
Read more
Insider Insights

World’s first CRISPR-based Gene Therapy Exa-cel …

NICE recommends gene therapy for severe beta-thalassaemia, offering hope for improved quality of lif…
Read more
161 Pharma & biotech companies worked with
11 We work with 11 of the top 20 pharma companies
95% Positive feedback from our training courses
57 We’ve supported pricing and access strategies in 57 countries worldwide

Our Services

From launching your product to access training

Launch Implementation

We will develop and implement a successful launch strategy for your product.

Find out more

Price Optimization

We build payer focussed pricing and market access strategies to enable commercial success.

Find out more

Market Access Training

We provide engaging training solutions that ensures your organisation stays ahead of the ever-changing market access landscape.

Find out more

Our mission

To enable patient access to your products

Unifying our internal strengths and external partnerships helps solve your pricing and market access challenges to drive patient access of your pharmaceutical products.

Our strategy

We have the expertise to get your products into doctors hands

Clearly and concisely communicate key scientific, economic and commercial messages to enable company employees to effectively communicate the product’s value.

How we work

Bespoke approach

Individual solutions to suit you

Flexible

We adapt our working style to reflect your needs

Real-world pharma experience

We have a wealth of practical knowledge & experience within the pharma industry & HTA bodies

Responsive

We react quickly and effectively to provide the best support possible

Updates & News

Latest research and publications

News
29.08.2024
ISPOR Europe 2024

We’re delighted to announce our participation at ISPOR Europe 2024 in Barcelona this November. We’ll…

Read more
04.10.2024
EU releases draft implementing act on Joint Scient…

The European Commission’s 4th implementing act outlines how health tech developers can obtain early …

Read more
Articles
17.09.2024
Can Real-World Evidence overcome uncertainty in Ra…

We examine how real-world evidence strategies help address uncertainties in rare disease treatments …

Read more
Articles
10.09.2024
Strategic approaches to achieving HTA approval for…

Achieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden…

Read more
Insider Insights
05.09.2024
NICE’s 1000th Appraisal: Iptacopan for Paroxysma…

The recent appraisal by the National Institute for Health and Care Excellence (NICE) for Iptacopan, …

Read more
News
03.09.2024
World Orphan Drug Congress Europe 2024

We’re thrilled to announce our participation at World Orphan Drug Congress Europe 2024 in Barcelona …

Read more
Articles
28.08.2024
How to integrate Market Access strategy with evide…

Introduction What is the secret to a successful drug launch? One crucial factor is establishing a cr…

Read more
Insider Insights
28.08.2024
NICE rejects first drug proven to slow Alzheimer 

Despite positive outcomes in treating Alzheimer’s disease, NICE cites small benefits and high costs …

Read more
Publications
22.08.2024
ISPOR Europe 2024 : Proactive Risk Surveillance fo…

This research leverages RWE using a quality-by-design (QbD) framework for proactive risk surveillanc…

Read more
Visit our resource library

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.